Skip to content

Effects of tumeric and Serrapeptase gel on reducing pain and improve range of motion in patients with osteoarthritis of the knee

Effects of topical tumeric (Domestica Val. Curcuma) and Serrapeptase on reducing pain and improve range of motion in patients with osteoarthritis of the knee ( a double blind randomized controlled trial)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140804018677N7
Enrollment
80
Registered
2021-02-26
Start date
2021-02-28
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Patients will be asked to gently rub a thin layer of gel containing 0.3% serapeptase and 0.3% bromolin every 4 hours for 10 days. Intervention 2: Control group: Pat

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: age>45y and having knee osteoarthritis according to American College of Rheumatology diagnostic criteria Knee pain with at least three of the followings: age>50, morning stiffness<30 min, crepitation, bone tenderness at knee, knee bone enlargement, warmness or pain in addition to osteophyte according to radiography Grade 2 or 3 of osteoarthritis according to Kellgren and Lawrence system Pain intensity between 5-8 at baseline according to VAS Able to walk independently

Exclusion criteria

Exclusion criteria: having joint arteritis, orthopedic or severe cardiovascular diseases having intra-articular injection of corticosteroids in past 3 months, as well as gel, and Platelet-rich plasma (PRP) in past year having allergic reaction to tumeric and Serrapeptase

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Baseline and at the end of the study. Method of measurement: VAS (visual analog scale).;Range of Motion and stiffness. Timepoint: Baseline and at the end of the study. Method of measurement: WOMAC.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodeh Razeghi Jahromi

Shahid Beheshti University of Medical Sciences

soodehrazeghi@gmail.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026